Literature DB >> 29165563

Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae.

Aurélie Jayol1,2,3,4, Patrice Nordmann1,2,3,5, Laurent Poirel1,2,3, Véronique Dubois4,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29165563     DOI： 10.1093/jac/dkx393

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  22 in total

1.  NG-Test Carba 5 for Rapid Detection of Carbapenemase-Producing Enterobacterales from Positive Blood Cultures.

Authors:  Julie Takissian; Rémy A Bonnin; Thierry Naas; Laurent Dortet
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

2.  Successful Treatment of Bacteremia Due to NDM-1-Producing Morganella morganii with Aztreonam and Ceftazidime-Avibactam Combination in a Pediatric Patient with Hematologic Malignancy.

Authors:  Claire Amaris Hobson; Stéphane Bonacorsi; Mony Fahd; André Baruchel; Aurélie Cointe; Nora Poey; Hervé Jacquier; Catherine Doit; Audrey Monjault; Olivier Tenaillon; André Birgy
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 3.  Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplantation: Management Principles.

Authors:  Olivia Smibert; Michael J Satlin; Anoma Nellore; Anton Y Peleg
Journal:  Curr Infect Dis Rep       Date:  2019-06-10       Impact factor: 3.725

4.  Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.

Authors:  Cécile Emeraud; Lelia Escaut; Athénaïs Boucly; Nicolas Fortineau; Rémy A Bonnin; Thierry Naas; Laurent Dortet
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

5.  [New antibiotics for severe infections due to multidrug-resistant pathogens : Definitive treatment and escalation].

Authors:  D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2019-11       Impact factor: 1.041

6.  Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates.

Authors:  Mustafa Sadek; Mario Juhas; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

Review 7.  An Update in Antimicrobial Therapies and Infection Prevention in Pediatric Lung Transplant Recipients.

Authors:  O C Smibert; M A Paraskeva; G Westall; Greg Snell
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

8.  Coinfections of Two Strains of NDM-1- and OXA-232-Coproducing Klebsiella pneumoniae in a Kidney Transplant Patient.

Authors:  Deisy A Contreras; Sean P Fitzwater; Deepa D Nanayakkara; Joanna Schaenman; Grace M Aldrovandi; Omai B Garner; Shangxin Yang
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 9.  Treatment of Infections by OXA-48-Producing Enterobacteriaceae.

Authors:  Adam Stewart; Patrick Harris; Andrew Henderson; David Paterson
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

10.  Case Report of an Extensively Drug-Resistant Klebsiella pneumoniae Infection With Genomic Characterization of the Strain and Review of Similar Cases in the United States.

Authors:  Fiorella Krapp; Egon A Ozer; Chao Qi; Alan R Hauser
Journal:  Open Forum Infect Dis       Date:  2018-04-06       Impact factor: 3.835
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.